Metabolic Brain DiseaseNeurosciencePeer-reviewed journal article
Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia
Buranee KanchanatawaniD, Sira SriswasdiiD, Michael H. J. MaesiD
Abstract
Stable phase schizophrenia is characterized by altered patterning in tryptophan catabolites (TRYCATs) and memory impairments, which are associated with PHEMN (psychosis, hostility, excitation, mannerism and negative) and DAPS (depression, anxiety and physio-somatic) symptoms. This study was carried out to examine the association between TRYCAT patterning, memory impairments, psychopathological features and health-related quality of life (HR-QoL) in schizophrenia.\n\nThe World Health Organization (WHO) QoL instrument-Abbreviated version (WHO-QoL-BREF), IgA/IgM responses to TRYCATs, cognitive tests, Scale for the Assessment of Negative Symptoms (SANS), Hamilton and Depression (HAMD) and Anxiety (HAMA) Rating Scales and the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF) were measured in 80 schizophrenia patients and 40 controls.\n\nNeural Network analysis shows that the total HR-Qol score is best predicted by (in descending order) FF, HAMA and SANS scores, Mini Mental State examination, hostility, ratio noxious/protective TRYCATs and HAMD score. Partial least Squares (PLS) analysis shows that 55.1% of the variance in Domain1 (physical) is predicted by PHEMN and DAPS latent vector (LV) scores, while 57.9% of domain2 (psychological), 32.7% of domain3 (social) and 55.0% of domain4 (environment) are explained by DAPS LV scores. TRYCATs and episodic/semantic memory impairments have specific indirect effects on domains 2, 3 and 4, which are mediated by DAPS symptoms, while the effects of TRYCATs on domain1 are mediated by PHEMN and DAPS symptoms. Picolinic acid, xanthurenic acid and 3-hydroxy-kynurenine decrease WHO-QoL scores, whilst anthranilic acid is protective.\n\nThe results show that lowered HR-Qol in schizophrenia is strongly predicted by noxious TRYCATs, impairments in episodic and semantic memory and DAPS symptoms, especially physio-somatic symptoms and anxiety. Neuro-immune pathways and the consequent cognitive impairments determine to a great extent lowered HR-QoL in schizophrenia.
- organism: human
- assay: proteomics
- research focus: differential expression
- approach: machine learning (classical)
- Citations
- 38
- FWCI
- 1.43
- Field percentile
- top 26%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A new schizophrenia model: immune activation is associated with induction of thetryptophan catabolite pathway and increased eotaxin levels which together determinememory impairments and schizophrenia symptom dimensions.
Sunee Sirivichayakul, Buranee Kanchanatawan, … Michael H. J. Maes·bioRxiv·Aug 16, 2018
- Phenome-wide and Genome-wide Analyses of Quality of Life in Schizophrenia
Raha Pazoki, Bochao Danae Lin, … Jurjen Justin Luykx·BJPsych OpenPeer-reviewed·Dec 9, 2020
- Kynurenine pathway in post-mortem prefrontal cortex and cerebellum in schizophrenia: relationship with monoamines and symptomatology.
Amira Ben Afia, Èlia Vila, … Borja García‐Bueno·Journal of NeuroinflammationPeer-reviewed·Sep 12, 2021
- Connectivity patterns of task-specific brain networks allow individual prediction of cognitive symptom dimension of schizophrenia and link to molecular architecture
Chen Ji, Veronika I. Müller, … Kaustubh R. Patil·Biological PsychiatryPeer-reviewed·Oct 3, 2020
- Working memory-related activity in catecholaminergic nuclei in schizophrenia
Nada Amekran, Verónica Mäki-Marttunen·bioRxiv·Aug 28, 2023
- Neuroanatomical Correlates of Negative Symptoms in Schizophrenia
SO M Vijayakumar Kamalakannan, Alie G. Male, … Theo G.M. van Erp·bioRxiv·Sep 22, 2025